It's all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial

Advanced cancer affects not only patients but also their informal caregivers, who often provide practical, emotional, and decision-making support. The authors note that caregiver perspectives are commonly overlooked, even though they can shape whether patients engage with treatment and trial participation. This issue is especially important for psychedelic-assisted care, because LSD remains highly stigmatised and may provoke concern or hesitation within families. The paper also frames meaning-centred psychotherapy (MCP) as a potentially helpful approach for existential distress in cancer, but says that the caregiver experience of a trial combining MCP with LSD microdosing had not been examined. The study aimed to investigate the hopes, beliefs, perceptions, and experiences of caregivers supporting advanced cancer patients enrolled in a randomised feasibility trial of LSD microdoses or placebo alongside MCP. The authors were interested in how caregivers experienced the trial itself, how they viewed the psychedelic component, and whether participation influenced their relationship with the patient and their own wellbeing. They present the work as a qualitative exploration of the caregiver side of a dyadic cancer intervention trial.

This was a qualitative study conducted as secondary research within the broader Psychedelic-Assisted Meaning-Centred Psychotherapy (PAM) feasibility trial. In the PAM trial, advanced cancer patients received individual MCP once weekly for 7 weeks and were randomly assigned to 13 microdoses of LSD or 13 placebo doses. The trial was double-blinded, and the extracted text states that participants, caregivers, researchers, and MCP therapists were all unaware of treatment allocation. The caregivers were nominated by the PAM trial participant as a close associate who might rely on them for personal care, emotional support, and/or domestic arrangements in an unpaid role. Eligibility also required fluency in English and age over 18 years. The extracted text does not clearly report the total number of caregivers recruited beyond indicating that 15 unique cancer patients were represented in the sample. Data were collected through semi-structured interviews, designed to encourage free discussion while allowing the interviewer to probe and clarify responses. Caregivers completed a demographic questionnaire before interviewing, covering age, ethnicity, and relationship to the patient. Each caregiver took part in two interviews: one at baseline, timed with the patient’s first treatment session, and a follow-up approximately 1 month after the patient’s final treatment session. Interviews were conducted by the researcher identified as F.C., transcribed verbatim, and analysed using reflexive thematic analysis. The primary researcher generated preliminary codes and themes, which were then reviewed and refined iteratively with L.R., A.W., and C.C. The authors state that all researchers and participants remained blinded to whether the PAM participant had received LSD or placebo throughout interviewing, analysis, theme generation, and manuscript preparation, so the study did not compare caregiver perspectives by treatment arm.

The sample included caregivers linked to 15 unique cancer patients in the PAM trial. Most caregivers were spouses or long-term partners (13), with one parent and one daughter. Ages ranged from the mid-30s to the mid-80s. Most participants were NZ European (12) and female (9). Five themes were identified. The first, “The oppression of the illness”, described the overwhelming impact of advanced cancer on caregivers’ lives. Caregivers spoke about the shock of diagnosis, constant medical treatment demands, disruption to family routines, communications with friends and wider networks, financial strain, uncertain futures, grief, and psychological burden. The authors emphasise that caregivers’ and patients’ wellbeing were closely intertwined, with mutual influence across the dyad. The second theme, “Supporting the trial experience”, captured how caregivers experienced the patient’s participation in the PAM trial. Many were supportive of enrolment, often because they hoped it would help the patient feel useful or find meaning, but some were initially hesitant because LSD was perceived as a powerful drug or because they were cautious about therapy. Caregivers also described the trial as a possible contribution to science or the community. At the same time, participation could make life busier and disrupt routines. The third theme, “Making the most of now, ideally”, reflected a shift towards valuing present-moment quality of life in response to advanced cancer. Caregivers described trying to prioritise enjoyable shared activities, avoid unnecessary conflict, and use the remaining time meaningfully. The trial was sometimes seen as part of this attempt to make the most of limited time. The fourth theme, “Hope is an antidote to desperation”, described how hope helped caregivers manage fear, uncertainty, and despair. Hope was linked to the patient’s wellbeing, relationship improvement, and the possibility that trial participation might help others in future. Some caregivers also expressed hope, albeit cautiously, for major or even miraculous improvement. The fifth theme, “The primacy of relationships”, showed that the illness and the trial sharpened the importance of close relationships. Caregivers reported greater appreciation of the relationship, more honesty and better communication, and a stronger sense that negative interactions were damaging. They described trying to respond more constructively and valuing mutual support within the dyad. Overall, the findings indicate that caregivers often viewed the trial positively, despite hesitations and practical burdens, and many associated it with improved communication, hope, meaning, and relationship quality. The results are qualitative and descriptive; the paper does not present quantitative outcome measures comparing LSD and placebo caregiver experiences.

The authors interpret the study as the first to explore caregiver experiences of supporting a patient in a trial of LSD microdosing alongside MCP, and they argue that it has broader relevance for cancer care. Their main interpretation is that caregiver and patient wellbeing are bidirectionally linked: what affects one tends to affect the other. They suggest that caregiving in advanced cancer is pervasive and that the trial context made this especially visible. Relative to earlier research, the authors say their findings reinforce prior evidence that advanced cancer places emotional, practical, financial, and psychological strain on informal caregivers, and that caregiver experiences can shape patient participation and outcomes. They also place their findings alongside previous work showing that stigma and misconceptions about psychedelics may affect willingness to participate in psychedelic trials, while education may support more informed decision-making. They note that the positive meaning-making, altruism, and relationship changes described by caregivers are consistent with research on cancer trial participation, meaning-centred psychotherapy, and the role of open communication in end-of-life care. The authors highlight several limitations and cautions. They note that the PAM trial was a feasibility study and was not powered to detect statistically significant change in demoralisation or related outcomes. They also stress that the qualitative design does not allow definitive conclusions about whether MCP plus LSD microdosing caused the reported benefits. In addition, because the study remained blinded, it could not examine whether caregiver experiences differed between the LSD and placebo conditions. In terms of implications, the authors argue that future clinical trials should include caregivers alongside patients so that the full cancer experience is captured. They suggest that caregiver wellbeing should be prioritised in palliative care because stressed caregivers are less able to support patients and may themselves suffer harm. The paper concludes that further research is needed on psychedelic-assisted or other psychological interventions that support both members of the dyad, rather than focusing solely on the patient.

The authors conclude that the patient-caregiver relationship is so important that interventions for advanced cancer are likely to be more effective when caregivers are included as well as patients. They say caregiver accounts suggested that MCP helped patients speak more openly about death and other difficult issues, and that the combined trial of MCP and LSD microdosing appeared to help address existential distress, although the qualitative design prevents firm causal claims. They recommend further work on interventions designed specifically for caregivers and argue that holistic cancer care should include hope, support, and relationship-enhancing approaches for the wider family.